(via TheNewswire)
![Universal Ibogaine Inc.](https://tnw-c.thenewswire.com/data/tnw/clients/logos/k3wFp7mZ.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/facebook.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/twitter.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/linkedIn.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/youTube.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/instagram.png)
Mr. Karos’ mandate will include expanding awareness of UI in the US-based investment community (including institutional investors, family offices, high net worth individuals and investment advisors), securing sources of expansion capital, as well as identifying business development opportunities in the addiction treatment industry. UI is currently in the process of finalizing an application to be listed for trading in the
UI also advises that it has granted incentive stock options (“Options”) to members of its recently expanded Executive team, as well as to several key, long-serving consultants to UI, and two new members of its’ Board of Directors who joined UI effective
Chief Clinics Officer ( | 3,000,000 |
Chief Financial Officer ( | 2,000,000 |
Director – Capital Markets ( | 2,000,000 |
Board members ( | 400,000 |
Consultants | 1,450,000 |
8,850,000 |
The grants are made under the Company’s 20% Fixed Stock Option Plan, which based on the total shares outstanding as at the date of the Company’s Amalgamation on
None of the current grantees have previously been issued any UI Options, and each Option will entitle the holder to acquire one UI common share at an exercise price of
Dr.
About
UI is a life sciences company, with a goal to develop a platform of addiction treatment clinics, which may eventually use ibogaine as a primary modality for theinterruption and ideally cessation of addictionsto primarily opioidssuch as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants.
UI separately plans to clinically develop ibogaine, a natural plant substance, as an authorized addiction interruption medicine for the treatment of Opioid Use Disorder. A Clinical Trial Application to
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", "potential", or other similar words, or statements that certain events or conditions "may", "should" or "could" occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Investor Relations:
dugan.selkirk@universalibogaine.com
Media Contact:
Related Links
https://universalibogaine.com
Copyright (c) 2021 TheNewswire - All rights reserved.
Copyright (c) 2021 TheNewswire - All rights reserved., source